Member Posts > Cardiol Therapeutics to Present at TD Cowen Conference, Strengthening Position in Cardiovascular Medicine
Cardiol Therapeutics Inc., a biotechnology company focused on advancing anti-inflammatory and anti-fibrotic treatments for heart disease, has announced its participation in the TD Cowen 45th Annual Health Care Conference. Taking place in Boston on March 5, 2025, at 11:10 AM EST, this event will allow Cardiol to present its latest research and development milestones to key industry stakeholders.
The company has a well-established presence at prominent healthcare conferences. Earlier this year, on February 11, 2025, Cardiol Therapeutics was featured at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, where it provided insights into its ongoing clinical trials. Additionally, on September 26, 2023, CEO David Elsley presented at the Cantor Fitzgerald 2023 Global Healthcare Conference, discussing the company's long-term vision for treating cardiovascular disease.
By consistently engaging with the medical and investment communities, Cardiol Therapeutics demonstrates its commitment to revolutionizing cardiovascular care through cutting-edge therapies, setting the stage for future breakthroughs in heart disease treatment.

#CardiolTherapeutics #MedicalResearch #HeartHealth #InvestorUpdates #BiotechIndustry #PharmaNews